Press Releases
June 2026
Evon Medics Announces Corporate Transition from LLC to Evon Medics, Inc.
Evon Medics announced its transition from a limited liability company to Evon Medics, Inc., marking a significant milestone in the company's growth. The announcement, shared by Charles Nwaokobia, COO & President, Evon Medics, reflects the organization's continued expansion and readiness for commercialization, strategic partnerships, and long-term investment opportunities.
April 2026
National Institutes of Health Highlights Evon Medics' COAT™ Clinical Research
The National Institutes of Health (NIH) recognized Evon Medics' groundbreaking research on its Computerized Olfactory Adaptive Training (COAT™) technology. Shared by Vamsi Reddy, Global Head of Product Development, Evon Medics, the announcement highlighted clinical evidence demonstrating improvements in cognitive performance and brain structure in individuals with early Alzheimer's disease.
March 2026
Evon Medics Clinical Trial Published in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Evon Medics announced the publication of its randomized feasibility clinical trial in the Alzheimer's Association's peer-reviewed journal, Alzheimer's & Dementia: Translational Research & Clinical Interventions. Led by Dr. Evaristus Nwulia, Co-Founder & CEO, Evon Medics, the study demonstrated significant improvements in cognition and gray matter volume following treatment with COAT™.
February 2024
National Institutes of Health SEED Program Recognizes Dr. Evaristus Nwulia and Evon Medics During Black History Month
The NIH SEED Program recognized Dr. Evaristus Nwulia, Co-Founder & CEO, Evon Medics, during Black History Month for his leadership in advancing neuroscience innovation. The feature celebrated his work developing novel therapeutic technologies for Alzheimer's disease while highlighting Evon Medics' growing impact on federally funded medical research.
May 2022
Evon Medics Awarded $2.8 Million NIH SBIR Fast-Track Grant to Advance Mobile Health Platform for Substance Use Disorder Management
Evon Medics received a $2.8 million NIH SBIR Fast-Track award from the National Institute on Drug Abuse (NIDA) to develop and evaluate a mobile health platform for remotely managing Substance Use Disorders. The project strengthens the company's mission to deliver innovative, technology-enabled solutions that improve access to behavioral healthcare.
July 2021
Evon Medics Recognized Among the 101 Best Medical Device Startups in Maryland
The Startup Pill named Evon Medics among the 101 Best Medical Device Startups in Maryland, recognizing the company's scientific innovation, research excellence, and commercial potential. The recognition reflects Evon Medics' growing reputation as a leader in developing breakthrough medical technologies for neurological and neurodegenerative disorders.
May 2021
Evon Medics Receives $2.5 Million NIH SBIR Phase II Award to Advance Home-Based Alzheimer's Disease Therapy
Evon Medics was awarded a $2.5 million NIH SBIR Phase II grant from the National Institute on Aging (NIA) to advance the clinical development of its Computerized Olfactory Training (COT) medical device. The award supports home-based treatment research aimed at improving outcomes for individuals living with Alzheimer's disease.
December 2020
Evon Medics Research Published in Dove Medical Press Journal
Evon Medics announced the publication of its research in a peer-reviewed Dove Medical Press journal examining repetitive odor identification and odor memory tasks. Led by Dr. Evaristus Nwulia, Co-Founder & CEO, Evon Medics, the study provided important scientific evidence supporting olfactory stimulation as a promising therapeutic approach for cognitive disorders.
October 2020
Evon Medics Team Raises More Than $3,000 for the Alzheimer's Association Walk to End Alzheimer's®
The Evon Medics team raised more than $3,000 in support of the Alzheimer's Association's Walk to End Alzheimer's®. Led by employees, partners, and supporters, the fundraising initiative demonstrated the company's commitment to advancing Alzheimer's awareness, supporting affected families, and contributing to the fight against the disease beyond the laboratory.
October 2020
Evon Medics Awarded $1.7 Million NIH SBIR Phase II Grant to Advance CBOT Therapy for Opioid Use Disorder
Evon Medics received a $1.7 million NIH SBIR Phase II award to develop and evaluate its Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) technology for Opioid Use Disorder. The grant supports the company's continued efforts to develop innovative, non-invasive digital therapeutics addressing addiction and other neurological conditions.
July 2026
Dr. Evaristus Nwulia Presents COAT™ Clinical Trial Findings at the Alzheimer's Association International Conference (AAIC®) 2026
Dr. Evaristus Nwulia, Co-Founder & CEO, Evon Medics, presented the latest clinical findings from the company's COAT™ technology at AAIC® 2026. His presentation highlighted peer-reviewed evidence demonstrating improvements in cognitive performance and brain structure, reinforcing Evon Medics' leadership in non-invasive therapeutics for Alzheimer's disease.
May 2026
Evon Medics Showcases COAT™ and MemoryDriver™ at the Amplify MedTech Startup Showcase
Vamsi Reddy, Global Head of Product Development, Evon Medics, together with Jamal and Dylan, represented Evon Medics at the Amplify MedTech Startup Showcase. The team demonstrated the company's COAT™ therapeutic platform and MemoryDriver™ brain training application while engaging investors, clinicians, and leaders across the medtech innovation ecosystem.
April 2026
Vamsi Reddy Speaks on Building Global Health Technology Products at HealthXAfrica
Vamsi Reddy, Global Head of Product Development, Evon Medics, delivered a presentation at HealthXAfrica on developing globally scalable health technology products. Drawing from Evon Medics' innovation journey, he shared insights into product strategy, clinical validation, commercialization, and building impactful digital health solutions for international markets.
February 2026
Evon Medics Officially Launches MemoryDriver™ 1.0
Evon Medics announced the official launch of MemoryDriver™ 1.0, an interactive brain training application designed to strengthen memory and spatial navigation through engaging, science-based exercises. The launch marked an important milestone in the company's mission to deliver accessible digital tools that support long-term brain health.
December 2025
Charles Nwaokobia Represents Evon Medics at The MedTech Conference Powered by AdvaMed
Charles Nwaokobia, COO & President, Evon Medics, represented the company at The MedTech Conference, powered by AdvaMed. He engaged with global industry leaders, investors, and innovators while highlighting Evon Medics' growing portfolio of neuroscience technologies and strategic vision for advancing neurological healthcare.
October 2024
Evon Medics Presents at the NINDS Therapeutics Development Conference in Chicago
The Evon Medics leadership team participated in the National Institute of Neurological Disorders and Stroke (NINDS) Therapeutics Development Conference in Chicago. The event provided opportunities to discuss translational neuroscience, therapeutic development, and strategic collaborations that accelerate innovative treatments for neurological disorders.
October 2024
Charles Nwaokobia Presents Evon Medics' Innovation at The MedTech Conference
Charles Nwaokobia, COO & President, Evon Medics, presented the company's innovative neuroscience technologies at The MedTech Conference. His presentation highlighted Evon Medics' progress in developing clinically validated, non-invasive medical devices designed to address Alzheimer's disease and other neurological conditions.
March 2023
Evon Medics Participates in the Governor's Institute 2023 Addiction Medicine Conference
The Evon Medics team attended the Governor's Institute 2023 Addiction Medicine Conference in Asheville, North Carolina, where they engaged healthcare professionals, researchers, and policymakers on emerging approaches to substance use disorder treatment and shared the company's work on innovative digital therapeutic technologies.
October 2022
Vamsi Reddy Represents Evon Medics at the Generis American Medical Device Summit 2022
Vamsi Reddy, Global Head of Product Development, Evon Medics, participated in the Generis American Medical Device Summit 2022, joining medical device executives and innovators to discuss product development, commercialization strategies, regulatory pathways, and emerging trends shaping the future of the global medtech industry.
June 2022
Charles Nwaokobia Represents Evon Medics at BIO International Convention 2022
Charles Nwaokobia, COO & President, Evon Medics, attended the BIO International Convention 2022, one of the world's largest biotechnology conferences. The event provided opportunities to engage global biotechnology leaders, explore strategic partnerships, and showcase Evon Medics' innovative neuroscience and medical device technologies.
June 2021
Charles Nwaokobia Discusses Evon Medics' Alzheimer's Technology with Steve Gurney
Charles Nwaokobia, COO & President, Evon Medics, joined Steve Gurney for an in-depth discussion on the company's innovative medical technology for Alzheimer's disease. The conversation highlighted Evon Medics' non-invasive therapeutic approach, scientific progress, and long-term vision for transforming neurological care.
March 2021
Evon Medics Selected to Present at the MedTech Innovator Road Tour
Evon Medics was selected to present its Computerized Olfactory Training (COT) technology during the prestigious MedTech Innovator Road Tour. The event provided the company with an opportunity to showcase its breakthrough Alzheimer's therapy before industry experts, investors, and leading medical technology organizations.
February 2021
Evon Medics Participates in the BioCapital Life Sciences Virtual Career Fair
Evon Medics participated in the BioCapital Life Sciences Virtual Career Fair, connecting with students, researchers, and professionals interested in careers across biotechnology and medical technology. The event highlighted the company's commitment to innovation, scientific excellence, and building the next generation of healthcare talent.
November 2020
Charles Nwaokobia Featured in CEOCFO Magazine Discussing Evon Medics' Mission to Transform Alzheimer's Care
Charles Nwaokobia, COO & President, Evon Medics, was interviewed by CEOCFO Magazine, where he discussed the company's mission to develop innovative, non-invasive therapies for Alzheimer's disease. The interview explored Evon Medics' scientific vision, commercialization strategy, and commitment to improving outcomes for patients and caregivers worldwide.
$
0
+
Non-dilutive funding
Awarded across SBIR/STTR grants and research programs — Alzheimer's disease, opioid use disorder, pain, and substance use disorder.
COAT™/COT
$3,091,180
SEP 2018
$225,000
JUN 2019
$225,000
APR 2021
$1,247,784
2R44AG061981-03A1
MAY 2022
$1,245,116
JUN 2022
$50,000
AUG 2022
$98,280
CBOT
$1,904,986
SEP 2019
$225,000
SEP 2020
$820,883
AUG 2021
$859,103
Modify-Pain/CBOT-PAIN
$3,129,999
SEP 2022
$499,999
MAR 2024
$1,349,130
MAR 2025
$1,280,870
EDITOR
$2,923,597
APR 2022
$330,680
FEB 2023
$55,000
JUN 2023
$1,318,829
JUN 2024
$1,219,088
EMRAST
$2,947,375
JUL 2023
$448,887
JUL 2024
$1,249,244
MAY 2025
$1,249,244
Non-SBIR Grants
$75,000
2022
$20,000
BGE Energizing Small Business Grant
2026
$55,000
TEDCO SBIR Matching Funds